Glaxosmithkline Plc (GSK) 43.66 $GSK
Dynavax Rebounds on Same PDUFA Date for Heplisav BLA
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 9:56AM CDT
Shares of Dynavax Technologies Corporation (DVAX) bounced back after the company indicated that the FDA will review its BLA for experimental hepatitis B vaccine, Heplisav on the current Prescription Drug User Fee Act (PDUFA) date of Dec 15, 2016.
DVAX: 12.55 (-0.31), ANIP: 61.54 (+0.83), GSK: 43.66 (-0.16)
The Zacks Analyst Blog Highlights: Inovio Pharmaceuticals, OraSure Technologies, GlaxoSmithKline, Sanofi and Spectrum Brands
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: Inovio Pharmaceuticals, OraSure Technologies, GlaxoSmithKline, Sanofi and Spectrum Brands
INO: 8.97 (-0.08), SPB: 131.01 (-1.38), GSK: 43.66 (-0.16), SNY: 40.12 (+0.52), OSUR: 8.93 (+0.16)
Glaxo Bexsero Meningitis B Immunization Shows Positive Data
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 9:32AM CDT
Glaxo (GSK) announced positive preliminary data from the world's first meningitis B immunization program on its Bexsero vaccine.
INVA: 11.41 (+0.03), ANIP: 61.54 (+0.83), GSK: 43.66 (-0.16), ANIK: 47.69 (-0.62)
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort(R) Turbohaler(R) in COPD at ERS International Congress
BusinessWire - Tue Sep 06, 8:45AM CDT
GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) in patients with chronic obstructive pulmonary disease (COPD), at the European Respiratory Society International Congress taking place in London this week.
INVA: 11.41 (+0.03), GSK: 43.66 (-0.16)
6 Drug Stocks in Focus as Zika Virus Fear Spreads
Arpita Dutt - Zacks Investment Research - Tue Sep 06, 7:00AM CDT
With no vaccines or treatments for Zika, the Zika outbreak is a cause for concern and the company that is the first to come out with a vaccine stands to benefit immensely.
INO: 8.97 (-0.08), SPB: 131.01 (-1.38), GSK: 43.66 (-0.16), SNY: 40.12 (+0.52), OSUR: 8.93 (+0.16)
Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: GlaxoSmithKline, Allergan, SFBC - Research and Markets
BusinessWire - Mon Sep 05, 9:25AM CDT
Research and Markets has announced the addition of the "Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016" clinical trials to their offering.
AGN: 239.55 (+1.13), GSK: 43.66 (-0.16)
Positive Results From the COPD Salford Lung Study Published in the NEJM and Presented at European Respiratory Congress
BusinessWire - Sun Sep 04, 4:00AM CDT
GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This unique study, which reported headline results in May 2016, was designed to evaluate the effectiveness and safety of Relvar(R) Ellipta(R) in patients with chronic obstructive pulmonary disease (COPD), compared with their 'usual care' administered in an everyday clinical practice setting. Data from the study are being presented at the European Respiratory Society (ERS) International Congress on Sunday 4th September in London, (abstract number OA249).
INVA: 11.41 (+0.03), GSK: 43.66 (-0.16)
GlaxoSmithKline Falls 1.06% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Sep 01, 12:57PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $42.88 to a high of $43.19. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $43.25 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 43.66 (-0.16)
SmarTrend Watching for Potential Rebound in Shares of GlaxoSmithKline After 1.06% Loss
Comtex SmarTrend(R) - Thu Sep 01, 12:55PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $42.88 to a high of $43.19. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $43.25 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 43.66 (-0.16)
Biotech Companies With Huge Potential
ACCESSWIRE - Wed Aug 31, 8:24AM CDT
LAS VEGAS, NV / ACCESSWIRE / August 31, 2016 / Outside of the energy sector, the past year, there has not been any sector under more pressure than biotechnology. As an example of the bearish bias, the ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ: BIB) has slumped from a record high last July at $106.10 to a low of $33.97 late in June, representing a top-to-bottom decline of 68%. For the most part, biotechs of all sizes have felt the pain. Markets are always cyclical and I believe the biotech beat down is reaching its bottom and will soon begin to reverse the trend. From a technical perspective, I think that BIB breaking over $50 again will be a sign of the reversal (it's currently around $43).
BIB: 48.05 (+0.46), GSK: 43.66 (-0.16), OCUL: 7.10 (-0.06)
M Pharmaceutical Inc. Announces Successful Findings from Second of Three Pilot Studies Validating Its Proprietary Reformulation of Orlistat, C-103 Eliminates 98% of Orlistat’s Gastrointestinal Adverse Effects
Filing Services Canada XHTML - Mon Aug 29, 2:03AM CDT
GSK: 43.66 (-0.16)
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Blackstone Group, Mylan, Lululemon and Whole Foods
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Blackstone Group, Mylan, Lululemon and Whole Foods
WFM: 29.29 (+0.21), BX: 26.92 (+0.30), MYL: 40.61 (+0.30), GSK: 43.66 (-0.16), LULU: 67.16 (-1.07)
Top Research Reports for August 25, 2016
Sheraz Mian - Zacks Investment Research - Thu Aug 25, 1:39PM CDT
Top Research Reports for August 25, 2016
WFM: 29.29 (+0.21), BX: 26.92 (+0.30), EA: 82.27 (-0.48), MYL: 40.61 (+0.30), GSK: 43.66 (-0.16), LULU: 67.16 (-1.07)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 45.90 (+0.01), MRK: 62.93 (+0.06), AMGN: 170.90 (+0.27), LLY: 79.70 (+1.11), GSK: 43.66 (-0.16)
Drug Makers Stocks under Review -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu Aug 25, 6:30AM CDT
Stock-Callers.com has initiated research reports on the following Major Drug Manufacturers in the Healthcare sector: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). On Wednesday, August 17, 2016, Brean Capital downgraded the sector to "Underweight" on technical indicators such as deteriorating relative strength, price momentum, and momentum of breadth. Learn more about these stocks by downloading their free research reports in PDF format at: http://stock-callers.com/registration
AZN: 32.96 (-0.22), LLY: 79.70 (+1.11), GSK: 43.66 (-0.16), BMY: 57.19 (+0.62)
GCC Countries Anti-Viral Drugs Market Outlook (2016-2021) - Key Players are Abbott, Gilead & GlaxoSmithKline - Research and Markets
BusinessWire - Tue Aug 23, 9:07AM CDT
Research and Markets has announced the addition of the "GCC Countries Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2016-2021)" report to their offering.
GSK: 43.66 (-0.16)
Teva Cinqaero Gets EU Nod for Severe Eosinophilic Asthma
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:23AM CDT
Teva Pharmaceutical's (TEVA) Cinqaero has gained approval in the EU for the treatment of adult patients with severe eosinophilic asthma.
AZN: 32.96 (-0.22), TEVA: 51.50 (+0.21), GSK: 43.66 (-0.16), ANIK: 47.69 (-0.62)
Mayne Pharma Acquires Rights to a Portfolio of Dermatology Foam Products Including Fabior(R) and Sorilux(R)
BusinessWire - Thu Aug 18, 4:54AM CDT
--Fabior(R) and Sorilux(R) are complementary dermatology assets to Doryx(R) and will be marketed through Mayne Pharma's established Specialty Brands Division
GSK: 43.66 (-0.16)
Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:59AM CDT
GlaxoSmithKline (GSK) announced that its HIV-focused company, ViiV Healthcare has initiated a phase III program to support regulatory filings for a two-drug regimen of Tivicay and Epivir for the treatment for HIV-1 infection.
PFE: 34.72 (-0.12), GSK: 43.66 (-0.16), CORT: 5.73 (+0.02)
Dynavax Rebounds on Same PDUFA Date for Heplisav BLA
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 9:56AM CDT
Shares of Dynavax Technologies Corporation (DVAX) bounced back after the company indicated that the FDA will review its BLA for experimental hepatitis B vaccine, Heplisav on the current Prescription Drug User Fee Act (PDUFA) date of Dec 15, 2016.
DVAX: 12.55 (-0.31), ANIP: 61.54 (+0.83), GSK: 43.66 (-0.16)
The Zacks Analyst Blog Highlights: Inovio Pharmaceuticals, OraSure Technologies, GlaxoSmithKline, Sanofi and Spectrum Brands
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: Inovio Pharmaceuticals, OraSure Technologies, GlaxoSmithKline, Sanofi and Spectrum Brands
INO: 8.97 (-0.08), SPB: 131.01 (-1.38), GSK: 43.66 (-0.16), SNY: 40.12 (+0.52), OSUR: 8.93 (+0.16)
Glaxo Bexsero Meningitis B Immunization Shows Positive Data
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 9:32AM CDT
Glaxo (GSK) announced positive preliminary data from the world's first meningitis B immunization program on its Bexsero vaccine.
INVA: 11.41 (+0.03), ANIP: 61.54 (+0.83), GSK: 43.66 (-0.16), ANIK: 47.69 (-0.62)
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort(R) Turbohaler(R) in COPD at ERS International Congress
BusinessWire - Tue Sep 06, 8:45AM CDT
GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) in patients with chronic obstructive pulmonary disease (COPD), at the European Respiratory Society International Congress taking place in London this week.
INVA: 11.41 (+0.03), GSK: 43.66 (-0.16)
6 Drug Stocks in Focus as Zika Virus Fear Spreads
Arpita Dutt - Zacks Investment Research - Tue Sep 06, 7:00AM CDT
With no vaccines or treatments for Zika, the Zika outbreak is a cause for concern and the company that is the first to come out with a vaccine stands to benefit immensely.
INO: 8.97 (-0.08), SPB: 131.01 (-1.38), GSK: 43.66 (-0.16), SNY: 40.12 (+0.52), OSUR: 8.93 (+0.16)
Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: GlaxoSmithKline, Allergan, SFBC - Research and Markets
BusinessWire - Mon Sep 05, 9:25AM CDT
Research and Markets has announced the addition of the "Seasonal Affective Disorder (SAD) Global Clinical Trials Review, H2, 2016" clinical trials to their offering.
AGN: 239.55 (+1.13), GSK: 43.66 (-0.16)
Positive Results From the COPD Salford Lung Study Published in the NEJM and Presented at European Respiratory Congress
BusinessWire - Sun Sep 04, 4:00AM CDT
GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This unique study, which reported headline results in May 2016, was designed to evaluate the effectiveness and safety of Relvar(R) Ellipta(R) in patients with chronic obstructive pulmonary disease (COPD), compared with their 'usual care' administered in an everyday clinical practice setting. Data from the study are being presented at the European Respiratory Society (ERS) International Congress on Sunday 4th September in London, (abstract number OA249).
INVA: 11.41 (+0.03), GSK: 43.66 (-0.16)
GlaxoSmithKline Falls 1.06% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Sep 01, 12:57PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $42.88 to a high of $43.19. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $43.25 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 43.66 (-0.16)
SmarTrend Watching for Potential Rebound in Shares of GlaxoSmithKline After 1.06% Loss
Comtex SmarTrend(R) - Thu Sep 01, 12:55PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $42.88 to a high of $43.19. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $43.25 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 43.66 (-0.16)
Biotech Companies With Huge Potential
ACCESSWIRE - Wed Aug 31, 8:24AM CDT
LAS VEGAS, NV / ACCESSWIRE / August 31, 2016 / Outside of the energy sector, the past year, there has not been any sector under more pressure than biotechnology. As an example of the bearish bias, the ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ: BIB) has slumped from a record high last July at $106.10 to a low of $33.97 late in June, representing a top-to-bottom decline of 68%. For the most part, biotechs of all sizes have felt the pain. Markets are always cyclical and I believe the biotech beat down is reaching its bottom and will soon begin to reverse the trend. From a technical perspective, I think that BIB breaking over $50 again will be a sign of the reversal (it's currently around $43).
BIB: 48.05 (+0.46), GSK: 43.66 (-0.16), OCUL: 7.10 (-0.06)
M Pharmaceutical Inc. Announces Successful Findings from Second of Three Pilot Studies Validating Its Proprietary Reformulation of Orlistat, C-103 Eliminates 98% of Orlistat’s Gastrointestinal Adverse Effects
Filing Services Canada XHTML - Mon Aug 29, 2:03AM CDT
GSK: 43.66 (-0.16)
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Blackstone Group, Mylan, Lululemon and Whole Foods
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Blackstone Group, Mylan, Lululemon and Whole Foods
WFM: 29.29 (+0.21), BX: 26.92 (+0.30), MYL: 40.61 (+0.30), GSK: 43.66 (-0.16), LULU: 67.16 (-1.07)
Top Research Reports for August 25, 2016
Sheraz Mian - Zacks Investment Research - Thu Aug 25, 1:39PM CDT
Top Research Reports for August 25, 2016
WFM: 29.29 (+0.21), BX: 26.92 (+0.30), EA: 82.27 (-0.48), MYL: 40.61 (+0.30), GSK: 43.66 (-0.16), LULU: 67.16 (-1.07)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 45.90 (+0.01), MRK: 62.93 (+0.06), AMGN: 170.90 (+0.27), LLY: 79.70 (+1.11), GSK: 43.66 (-0.16)
Drug Makers Stocks under Review -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu Aug 25, 6:30AM CDT
Stock-Callers.com has initiated research reports on the following Major Drug Manufacturers in the Healthcare sector: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). On Wednesday, August 17, 2016, Brean Capital downgraded the sector to "Underweight" on technical indicators such as deteriorating relative strength, price momentum, and momentum of breadth. Learn more about these stocks by downloading their free research reports in PDF format at: http://stock-callers.com/registration
AZN: 32.96 (-0.22), LLY: 79.70 (+1.11), GSK: 43.66 (-0.16), BMY: 57.19 (+0.62)
GCC Countries Anti-Viral Drugs Market Outlook (2016-2021) - Key Players are Abbott, Gilead & GlaxoSmithKline - Research and Markets
BusinessWire - Tue Aug 23, 9:07AM CDT
Research and Markets has announced the addition of the "GCC Countries Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2016-2021)" report to their offering.
GSK: 43.66 (-0.16)
Teva Cinqaero Gets EU Nod for Severe Eosinophilic Asthma
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:23AM CDT
Teva Pharmaceutical's (TEVA) Cinqaero has gained approval in the EU for the treatment of adult patients with severe eosinophilic asthma.
AZN: 32.96 (-0.22), TEVA: 51.50 (+0.21), GSK: 43.66 (-0.16), ANIK: 47.69 (-0.62)
Mayne Pharma Acquires Rights to a Portfolio of Dermatology Foam Products Including Fabior(R) and Sorilux(R)
BusinessWire - Thu Aug 18, 4:54AM CDT
--Fabior(R) and Sorilux(R) are complementary dermatology assets to Doryx(R) and will be marketed through Mayne Pharma's established Specialty Brands Division
GSK: 43.66 (-0.16)
Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:59AM CDT
GlaxoSmithKline (GSK) announced that its HIV-focused company, ViiV Healthcare has initiated a phase III program to support regulatory filings for a two-drug regimen of Tivicay and Epivir for the treatment for HIV-1 infection.
PFE: 34.72 (-0.12), GSK: 43.66 (-0.16), CORT: 5.73 (+0.02)
